Slovenia has added major pharmaceutical manufacturing capacity as regulators in its potential overseas markets reconsider how biosimilar medicines must be tested. Lendava's municipality reported on 29 September 2026 that Lek, part of Sandoz, had opened a biopharmaceutical centre representing investment of more than €400 million and bringing more than 300 new jobs. The facility forms part of the group's European development and production network.1
The municipality describes the centre as:
namenjen proizvodnji učinkovin za podobna biološka zdravila
intended to produce active substances for biosimilar medicines.1
Biosimilars must demonstrate similarity to an existing reference medicine. Their route to overseas customers therefore depends on the evidence accepted by the destination's regulator, alongside the ability to manufacture consistently. The European Medicines Agency's latest approach places greater weight on detailed analytical comparisons when deciding whether additional clinical efficacy trials are necessary.2
Europe's adopted approach retains scientific conditions
EMA's medicines committee adopted its reflection paper on 16 March 2026. It describes circumstances in which analytical evidence and pharmacokinetic data, which track how the body processes a medicine, can establish biosimilarity without a separate comparative efficacy study. This is conditional on adequate understanding of the substance and sufficiently sensitive testing, with appropriate assessment of safety.2
The paper does not replace existing quality guidance. It calls for validated manufacturing processes, controls and consistent production batches. For a Slovenian producer, the commercial implication is a possible change in the evidence needed to support a product's market entry, while the requirement to demonstrate reliable manufacturing remains. A reduced clinical programme is not an exemption from demonstrating product comparability.2
The American proposal concerns evidence from outside the United States
On 9 March 2026, the US Food and Drug Administration announced draft recommendations allowing greater use of clinical data involving a comparator medicine approved outside America. Where scientifically justified, applicants could avoid an additional three-way pharmacokinetic study comparing their biosimilar, the US reference product and the overseas comparator. FDA also proposed removing its earlier recommendation for at least one direct clinical pharmacokinetic comparison with the US reference product.3
FDA estimated potential savings of up to 50% of pharmacokinetic study costs, or approximately US$20 million. That is the agency's development-cost estimate, not a saving reported by Lek or a forecast of Slovenian export earnings.3
The current Revision 4 document remains draft guidance, marked as not for implementation. It asks applicants to scientifically justify the relevance of overseas-comparator data and encourages early discussions with FDA. For manufacturers seeking American access, the proposal could reduce duplicated development work; it does not confer a US product licence or establish that Lendava's output has been approved for that market.4
The local announcement establishes the opening, investment and employment. It provides no destination-specific shipment volumes or evidence that either regulatory initiative caused the factory investment. The effect on future export production therefore remains prospective.1
Further European revision also remains unfinished. EMA's separate consultation on a concept paper for revising its general biosimilar guideline closed on 31 October 2026. The agency still lists the earlier guideline as the current effective version. The next question is how the proposed revision develops alongside the already adopted reflection paper.5